Загрузка...
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
Today, monoclonal antibodies (mAbs) are a widespread and necessary tool for biomedical science. In the hematological cancer field, since rituximab became the first mAb approved by the Food and Drug Administration for the treatment of B-cell malignancies, a number of effective mAbs targeting lineage-...
Сохранить в:
| Опубликовано в: : | Front Immunol |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5776327/ https://ncbi.nlm.nih.gov/pubmed/29387053 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2017.01936 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|